TC091 / TiCARos - LARVOL DELTA

Matica Bio Labs to manufacture Ticaros' TC091 CAR-T therapy for solid tumors (Chosun Biz) - "Matica Bio Labs, a contract development and manufacturing organization (CDMO) subsidiary of CHA Biotech, said on the 10th that it signed a contract to manufacture clinical trial drugs for immuno-oncology corporations Ticaros. The company did not disclose the contract amount. Under the contract, Matica Bio Labs will produce and supply the clinical trial drug for 'TC091', a solid tumor-targeting CAR-T Therapy that Ticaros is developing."

Commercial • Solid Tumor

Ticaros Receives Support from Ministry of Food and Drug Safety for CAR-T Treatment Product Development [Google translation] (HIT News) - "TiCaros...announced on the 16th that TC091, a CAR-T treatment candidate targeting solid cancer, was selected for the Ministry of Food and Drug Safety’s Bio-challenger program...BioChallenger is a product development support system targeting advanced biopharmaceuticals that respond to unmet medical needs...The selection criteria are that it is a domestically developed product, targets a serious life-threatening disease, and has development potential confirmed through the mechanism of action and non-clinical data. Innovation, medical significance, and commercialization potential are also included in the evaluation criteria....The TC091 selected this time is a solid tumor targeting CAR-T treatment designed based on TiCaros' unique CLIP backbone structure."

Clinical • Solid Tumor